Document Detail


Efficacy and safety of topical tazarotene: a review.
MedLine Citation:
PMID:  20213916     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris. OBJECTIVES: To review a decade of experience using tazarotene as a monotherapy or as combination therapy for approved and other indications: acne, psoriasis, photoaging, basal cell carcinomas and various keratinization disorders. METHODS: We reviewed the published literature available on PubMed for safety and efficacy of topical tazarotene gel or cream preparations. RESULTS/CONCLUSIONS: Tazarotene, in both gel and cream formulations, has been used both as monotherapy and as an adjuvant therapy. For psoriasis it has been combined with steroids, calcipotriene and phototherapy, and for acne, with antibiotics. Tazarotene has been shown to upregulate the tumor suppressor, tazarotene induced gene 3, which is overexpressed in psoriasis and skin cancer. Adverse effects are limited to mild to moderate local irritation and erythema as seen with the 'retinization period' of other topical retinoid therapies. Daily application of tazarotene is effective with sustained benefits and limited local side effects.
Authors:
Rakhashandra Talpur; Katherine Cox; Madeleine Duvic
Related Documents :
3912976 - The treatment of herpes zoster infections.
16265796 - Adaptation to bereavement.
24651346 - Summary of: regenerative endodontics.
24111706 - Development of anterior inferior cerebellar artery pseudoaneurysm after gamma knife sur...
15765046 - Stenosis of the abdominal aorta caused by fibromuscular dysplasia.
15083006 - Accident-induced late complaint of odontoid nonunion.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  5     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2010-03-08     Completed Date:  2010-05-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  195-210     Citation Subset:  IM    
Affiliation:
University of Texas, MD Anderson Cancer Center, Department of Dermatology, Houston, Texas, USA. rtalpur@mdanderson.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acne Vulgaris / drug therapy*,  physiopathology
Administration, Cutaneous
Animals
Carcinoma, Basal Cell / drug therapy,  pathology
Dermatologic Agents / administration & dosage,  adverse effects,  therapeutic use*
Humans
Nicotinic Acids / administration & dosage,  adverse effects,  therapeutic use*
Psoriasis / drug therapy*,  physiopathology
Receptors, Retinoic Acid / drug effects,  genetics
Skin Aging / drug effects
Up-Regulation / drug effects
Chemical
Reg. No./Substance:
0/Dermatologic Agents; 0/Nicotinic Acids; 0/RARRES3 protein, human; 0/Receptors, Retinoic Acid; 118292-40-3/tazarotene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modification of Derzhavin sphyncteroplasty and elimination of symphysis diastasis of the pubic bone ...
Next Document:  Using spatial occlusion to explore the control strategies used in rapid interceptive actions: Predic...